Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to allchildren from 12 to 18 years old. In the specific population of teenagers living withjuvenile arthritis, the vaccine seems to be safe and well tolerated. It has been shownpreviously that this population has a vaccine coverage lower than the global populationeven though few datas are available on this topic The aim of this resarch is to study thevaccination coverage against the SARS-Cov2 virus and more specifically the reasons whyadolescents were or were not vaccinated in the population of adolescents with juvenilearthitis followed up in Angers, Nantes and Rennes. For this purpose, a review of themedical record will be done and a questionnaire will be adressed to the family ofpatients in order to collect informations about the disease, the treatments, the motivesor obstacles to vaccination. Secondaries end points are safety of the vaccination,consequences on the juvenile arthritis (such as changes in the medication, flare-up ofthe illness) and the occurence of covid infection after vaccination.